Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the must-buy US stocks to buy right now. On April 2, Roivant Sciences Ltd.

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...

BioCardia announces data verification completion for Phase 3 CardiAMP HF study on heart failure treatment, with results due March 30, 2025. BioCardia, Inc. has completed source data verification and ...

According to the Federal Railroad Administration (FRA), between 2013 and 2015, accidents associated with wheel failures represented 11% of all equipment-caused accidents, a figure based on November ...

Moderna is terminating the development of an mRNA vaccine in congenital cytomegalovirus (CMV) after it failed to show any significant benefit in a Phase III trial. Top line data from the CMVictory ...

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of ...

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the randomization of the last participant was completed earlier this ...